Engrail Therapeutics
Founded in 2019, Engrail Therapeutics is dedicated to developing and commercializing neuro drugs. Its primary focus is on treating diseases related to the nervous system. The company's flagship compound, ENX-101, is a preclinical modulator of a receptor for GABA, a neurotransmitter in the brain.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
NeuroCycle Therapeutics
Acquisition in 2021
NeuroCycle Therapeutics, founded in 2018 and based in Cambridge, Massachusetts, is a biopharmaceutical company specializing in the development of small molecule drugs that target the nervous system. The company's primary focus is on sub-type selective GABA-A modulation, aiming to deliver next-generation treatments for chronic itch, pain, and certain refractory forms of pediatric epilepsy. Their lead candidate, NCT10004, has demonstrated significant efficacy across various models without causing sedation, immune suppression, dependency/addiction issues, or losing effectiveness over time.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.